Trial Profile
An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Pravastatin (Primary) ; Zoledronic acid (Primary)
- Indications Progeria
- Focus Therapeutic Use
- Acronyms ProLon2
- 23 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 11 Jun 2021 Planned End Date changed from 1 Jul 2020 to 1 Dec 2022.
- 11 Jun 2021 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2021.